Patheon Invests $45 Million in Facilities

Article

Patheon will add spray drying, sterile manufacturing, and packaging capabilities to four facilities.

Patheon announced plans to invest $45 million in spray drying, sterile manufacturing, and packaging and serialization equipment and facilities at four sites in the company’s global network, according to a June 29, 2017 press statement.

The expansions include a 15,000-sq.-ft. suite at the company’s Florence, SC facility that will contain two spray dryers for development and commercial scale spray-dried dispersion (SDD) services. The suite is scheduled to be online in 2019.

The company also announced plans to expand existing development SDD capabilities at the Bend, OR site with a new cGMP analytical lab, manufacturing suite, and additional development-scale spray drying.

At the Monza, Italy site, Patheon plans to invest in in a commercial sterile product manufacturing facility that will house three, 40-sq.-m lyophilizers with integrated filling equipment for lyo and liquid formulations for small and large molecules in a range of vial specifications. The equipment will feature clean-in-place systems and auto loading for the lyophilizers contained in restricted access barrier systems. Other planned additions include a sterile product development suite with two lyophilizers, sterile vial filling line, and analytical laboratory. The facility is scheduled to be operational in mid-2019.

The company also announced expansion of the packaging and serialization capabilities at its Greenville, NC site including a new filling and packaging suite and an upgraded packaging line. The new 4,800-sq.-ft. suite, scheduled tocome online in the fall of 2017, will feature a filling and packaging line, and an Optel serialization system with cameras, pharma proof stations, line master, and bottle and bundle tracker equipment.

Source: Patheon

 

 

Recent Videos
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content
© 2024 MJH Life Sciences

All rights reserved.